P53 signaling is often dysregulated in CRC; patients with the mutant p53 gene may be resistant to current therapies, leading to a poor prognosis.38TRAIL-R2 (TNFRSF10B; geneID: 8795) expression is also induced by F7+F3 treatment. This evidence concerns the gene TNFRSF10B and colorectal carcinoma.